Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine 30/60 mg Once Daily vs Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome
2018-001615-78Phase 3
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Juvenile Fibromyalgia Syndrome (JFMS) comparing Duloxetine arm with Placebo arm (2 arms). Primary endpoint: Change in 24-hour average pain severity.
02
Drugs
duloxetine
03
Conditions
Juvenile Fibromyalgia Syndrome (JFMS)
Beyond the preview
Go deeper on 2018-001615-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001615-78.